FdaApplication
NDA 211243
Identifiers
- fda_app_no: NDA211243
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2019-03-05 |
Revenue by product
SPRAVATO
| Period | Revenue |
|---|---|
| Q2 2026 | $584.0M |
| Q1 2026 | $468.0M |
| Q4 2025 | $503.0M |
| Q3 2025 | $459.0M |
| Q2 2025 | $414.0M |
| Q1 2025 | $320.0M |
| Q4 2024 | $297.0M |
| Q3 2024 | $284.0M |
| Q2 2024 | $271.0M |
| Q1 2024 | $225.0M |
| Q4 2023 | $206.0M |
| Q3 2023 | $183.0M |
| Q2 2023 | $169.0M |
| Q1 2023 | $131.0M |
| Q4 2022 | $119.0M |
| Q3 2022 | $100.0M |
| Q2 2022 | $85.0M |
| Q1 2022 | $70.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SPRAVATO | ESKETAMINE HYDROCHLORIDE | EQ 28MG BASE | SPRAY;NASAL |
1 product